• Collaboration is a 50/50 cost and profit-sharing model and combines Telix's expertise in radiopharmaceutical development and manufacturing with Regeneron's leading antibody discovery/development platforms and oncology experience.
  • Telix to receive US$40 million upfront for four initial programs with optionality on a per program basis to co-fund commercialization and profit-share or earn up to an aggregate of US$2.1 billion in development and commercial milestone payments plus low double-digit royalties.